How much has Teladoc Health raised?
Teladoc Health is a public company (NYSE: TDOC), so the most useful current funding read is its filings, revenue scale, cash flow, guidance, and acquisition capacity rather than private round totals.
- Total raised
- Public company; private total not the current constraint
- Disclosed rounds
- Pre-IPO/private history plus public filings
- Latest round
- Public-market financing and operating cash flow
- Latest valuation
- NYSE: TDOC
- First raised
- 2002
- Notable backer
- Public shareholders
Teladoc Health's funding rounds
Teladoc Health's capital path moved from founding and growth capital into public-company financing.
- 2002FoundedTeladoc is founded as an early telehealth provider.
- 2015IPOTeladoc lists publicly on NYSE.
- 2020Livongo acquisitionTeladoc acquires Livongo in a large digital-health combination.
- 2025Full-year resultsTeladoc reports $2.530B of 2025 revenue.
- 2026Q1 resultsTeladoc reports $613.8M of Q1 revenue, with Integrated Care up and BetterHelp down.
How much has Teladoc Health raised in total?
Teladoc Health is best analyzed as a public company as of June 2026. Any pre-IPO venture or private-equity history is less useful for current selling than the company's listed status, revenue base, cash generation, debt capacity, and investor commitments.
The current scale marker is $2.530B 2025 revenue; $613.8M Q1 2026 revenue. That tells sellers the company can fund enterprise purchases, but those purchases must survive budget ownership, procurement, security, compliance, and ROI review.
Who are Teladoc Health's investors?
The relevant investor base is the public shareholder base behind NYSE: TDOC. Management teams at this stage are accountable to public-market expectations for growth, margin, cash flow, guidance, and risk control.
That accountability affects buying behavior: projects tied to reported metrics, margin expansion, regulatory readiness, or customer growth are easier to justify than speculative tooling.
Why did valuation or capital priorities move?
Valuation for a public healthcare company moves with growth, margins, reimbursement, utilization, clinical evidence, customer retention, regulatory risk, and capital-market sentiment. Teladoc Health's latest public materials emphasize $2.530B 2025 revenue; $613.8M Q1 2026 revenue, which is the clearest factual anchor for current account planning.
For seller strategy, avoid treating valuation as the budget. Translate the company's stated operating priorities into a business case owned by a specific executive function.
Is Teladoc Health profitable, and will it need more capital?
Profitability and capital needs should be read from the latest annual report, quarterly results, cash-flow statement, and guidance. Public healthcare and life-science companies can have revenue scale while still prioritizing profitability, cash preservation, restructuring, R&D, or commercial expansion.
The safe sales assumption is mature budget governance: finance will ask why the project matters now, what metric it moves, and how implementation risk is controlled.
What does Teladoc Health's funding mean if you sell into them?
The seller signal is buying capacity with a high proof bar. Teladoc Health can fund software, data, services, infrastructure, compliance, clinical, and go-to-market projects when they match a board-visible or executive-visible priority.
Procurement is likely to favor vendors with healthcare references, security documentation, integration readiness, implementation support, and clear commercial terms.
As of June 2026.Sources:Teladoc FY 2025 resultsTeladoc Q1 2026 results
Teladoc Health — frequently asked questions
